Biofrontera Inc

-0.02 (-0.23%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)11.71M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$7.03 Million
Adjusted EPS-$4.26
See more estimates
10-Day MA$8.54
50-Day MA$9.85
200-Day MA$12.66
See more pivots

Biofrontera Inc Stock, NASDAQ:BFRI

120 Presidnetial Way, Suite 330, Woburn, Massachusetts 01801
United States of America
Phone: +1.781.245.1325
Number of Employees: 81


Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.